EcoDrugPlus

Tyrosine Hydroxylase

Ensembl ID : ENSCGOG00000011200
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSCGOG00000004966
Gene Symbol: TYK2
3 Cross references
196 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSCGOG00000019073
Gene Symbol: TIE1
3 Cross references
207 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSCGOG00000009110
Gene Symbol: LOC115017096
3 Cross references
198 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSCGOG00000008394
Gene Symbol: LOC115013079
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSCGOG00000023957
Gene Symbol: LOC115022351
3 Cross references
196 Possible Orthologues:

Tyrosine-Protein Kinase Fyna-Like

Ensembl ID : ENSCGOG00000024700
Gene Symbol: LOC115027270
3 Cross references
192 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSCGOG00000004710
Gene Symbol: LOC115022365
3 Cross references
197 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSCGOG00000018902
Gene Symbol: UTS2R
3 Cross references
92 Possible Orthologues:

Utrophin

Ensembl ID : ENSCGOG00000012219
Gene Symbol: UTRN
3 Cross references
254 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSCGOG00000012743
Gene Symbol: VEGFA
3 Cross references
198 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSCGOG00000019110
Gene Symbol: LOC115021761
3 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).